When patients with breast cancer were treated with the combination of bevacizumab and doxorubicin, HBQ1 was often differentially expressed (Borgan et al., 2013; Bae et al., 2022) and IGKV1D-8 was primarily involved in immune response (Gaudet et al., 2011). Here, HBQ1 is linked to breast carcinoma.